Monopar Therapeutics (MNPR) Total Non-Current Liabilities (2020 - 2025)

Monopar Therapeutics (MNPR) reported Total Non-Current Liabilities of $2.9 million for Q4 2025, down 44.99% on a YoY basis from $5.3 million in Q4 2024, and up 9.5% sequentially from $2.6 million in Q3 2025.

Monopar Therapeutics (MNPR) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends

Monopar Therapeutics (MNPR) has 3 years of Total Non-Current Liabilities data on file, last reported at $2.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 44.99% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (down 44.99% YoY), and the FY2025 full-year result was $2.9 million, down 44.99% from the prior year.
  • Total Non-Current Liabilities grew to $2.9 million in Q4 2025, from $2.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $5.3 million in Q4 2024 to a low of $1.5 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 4.45 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 110.28 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 19.49 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.98 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 746.94 Mn
10 Monopar Therapeutics 800.03 Mn 738.20 Mn - 2.89 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 2.89 Mn
Sep 30, 2025 2.64 Mn
Jun 30, 2025 1.66 Mn
Mar 31, 2025 1.49 Mn
Dec 31, 2024 5.25 Mn
Sep 30, 2020 54,628.00
Jun 30, 2020 75,021.00